Clinical Trial Update: A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD) [Phase 2]

View source ↗

Summary

A Phase II prospective randomized double-masked crossover trial is evaluating the safety and efficacy of RHPRG4 for ocular graft-versus-host disease in patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Graft-versus-host Disease

Drugs mentioned

• RHPRG4

Snippet

Sponsor: Lubris Bio Pty Ltd | Conditions: Ocular Graft Versus Host Disease | Phase 2 | Status: RECRUITING